جستجوی مقالات مرتبط با کلیدواژه « Hyperlipidemia » در نشریات گروه « پزشکی »

Silymarin is utilized in the treatment of liver conditions primarily because of its antioxidant properties and its ability to lower blood lipid levels. Propofol, an anesthetic and antioxidant, is harmful to patients with hyperlipidemia. The aim of this study was to investigate the beneficial effects of silymarin and propofol on liver enzymes and blood indices. We also studied the impacts of propofol and silymarin on propofol-induced hyperlipidemia in male Wistar rats.

The rats were divided into four groups: 1) controls; 2) silymarin; 3) propofol; and, 4) combined propofol and silymarin. On the 22nd day after the treatments, all rats were anesthetized, and their blood samples were collected to estimate the levels of AST, ALT, ALP, LDH, TG, TC, LDL-C, and HDL-C. After being sacrificed, the liver was removed from each rat to determine the levels of MDA, GPx, GSH, and CAT. Moreover, histopathological examinations were performed on all liver samples.

Silymarin and propofol, used either separately or in combination, had a favorable effect on the indicators of oxidative stress and the liver’s antioxidant markers. The propofol treatment alone significantly increased the blood lipid parameters. The administration of Silymarin had a modulating effect on propofol-induced hyperlipidemia in rats.

Propofol and silymarin had favorable effects on the liver; however, propofol increased the blood lipids due to its lipid structure, which is a warning for patients with hyperlipidemia. In this regard, silymarin may be considered a protective option, making it a potential treatment for patients experiencing hyperlipidemia induced by propofol.

Strongyloides stercoralis is one of the soil-transmitted helminths (STH) in tropical and subtropical regions. The role of lipid profile has been investigated in the survival of larval stages of helminths, but there is limited information about the role of lipid profiles and strongyloidiasis. Hence, we aimed to investigate the seroprevalence of S. stercoralis infection in patients with hyperlipidemia is compared with the nonhyperlipidemia.

In 2023, participants were selected from the laboratory of Porsina Hospital in Guilan Province, northern Iran and their lipid profiles including TG, CHOL, LDL, HDL, and VLDL were measured. They were divided into two groups of case and control and matched based on sex and age. S. stercoralis Ab (IgG) was measured by ELISA methods, using the NovaTec kit. Finally, statistical analysis was performed.

Each case and control group consisted of 105 participants, from 13 to 80 years old. 56.66% were female and 43.33% were male. The sero-prevalence of S. stercoralis was found 4.76% in the case group compared to 0.95% in the control group. We found an association between TG fall and VLDL with sero-prevalence of S. stercoralis in hyperlipidemia group (P= 0.034), but other lipid profiles did not show a significant association. A significant relationship was found between contact with dogs and seroprevalence of S. stercoralis (P=0.001).

The sero-prevalence of S. stercoralis in the case group was 5 times higher than the control group. A significant association between TG and VLDL fall with S. stercoralis Ab (IgG) was observed, but future studies with more sample sizes are suggested to investigate the anti-atherogenic effect of S. stercoralis. Also, a genetic assessment of S. stercoralis and the host (humane and dogs) is recommended to research zoonotic potential in epidemic areas.

 The objective of this study was to develop a nanoencapsulated platform for coenzyme Q10 nanoparticles (coQNPs) or selenium nanoparticles (SeNPs) and explore their potential therapeutic benefits in treating hyperlipidemia and combating simvastatin (SV)-induced myopathy and adverse reactions in hyperlipidemic rats.

 The physical and chemical properties of the solid nanoparticles, coQNPs, and SeNPs were characterized, including zeta potential studies. Male Wistar albino rats were treated with various interventions for 112 days, including a nano-vehicle only, high-fat diet (HFD), HFD with SV alone, or with coQNPs or/and SeNPs for the last 30 days.

 The coQNPs and SeNPs exhibited uniform spherical shapes with high encapsulation efficiency (EE% 91.20±2.14 and 94.89±1.54, respectively). The results demonstrated that coQNPs and SeNPs effectively reduced hyperlipidemia, insulin resistance, SV-induced myopathy, and hepatotoxicity. However, combining SV with coQNPs and SeNPs resulted in severe liver and muscle damage. Treatment with SV and SeNPs or SV and coQNPs alone showed significant improvements compared to SV treatment alone.

 These findings suggest that the CoQNPs or SeNPs platforms offer advanced relief for hyperlipidemia and insulin resistance while limiting adverse effects such as myopathy and hepatotoxicity.

This guideline is the first Iranian guideline developed for the diagnosis, management, and treatment of hyperlipidemia in adults. The members of the guideline developing group (GDG) selected 9 relevant clinical questions and provided recommendations or suggestions to answer them based on the latest scientific evidence. Recommendations include the low?density lipoprotein cholesterol (LDL?C) threshold for starting drug treatment in adults lacking comorbidities was determined to be over 190 mg/dL and the triglyceride (TG) threshold had to be >500 mg/dl. In addition to perform fasting lipid profile tests at the beginning and continuation of treatment, while it was suggested to perform cardiovascular diseases (CVDs) risk assessment using valid Iranian models. Some recommendations were also provided on lifestyle modification as the first therapeutic intervention. Statins were recommended as the first line of drug treatment to reduce LDL?C, and if its level was high despite the maximum allowed or maximum tolerated drug treatment, combined treatment with ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, or bile acid sequestrants was suggested. In adults with hypertriglyceridemia, pharmacotherapy with statin or fibrate was recommended. The target of drug therapy in adults with increased LDL?C without comorbidities and risk factors was considered an LDL?C level of <130 mg/dl, and in adults with increased TG without comorbidities and risk factors, TG levels of <200 mg/dl. In this guideline, specific recommendations and suggestions were provided for the subgroups of the general population, such as those with CVD, stroke, diabetes, chronic kidney disease, elderly, and women.

Obesity is an abnormal fat accumulation that adversely affects human health. Studies reported several vitamin deficiencies in obese patients. The current study investigates the deficiencies of vitamins D, B6, and B12 among Jordanian adults with hyperlipidemia and demonstrates the association between serum vitamin levels and metabolic and lipid profile parameters.

 Sixty male subjects were divided into 40 hyperlipidemic patients (age: 45.9 yr. ±10.2) and 20 controls (age: 41.2 yr. ±10.7). The blood levels of triglycerides, total cholesterol, high density lipoprotein (HDL)-cholesterol, hemoglobin A1c, and vitamins D, B6, and B12 were measured.

The hyperlipidemic patients showed significantly increased triglycerides, total cholesterol, non-HDL, cholesterol/HDL ratio, low-density lipoprotein (LDL)- cholesterol levels, and decreased HDL-cholesterol levels compared to the controls. No significant differences were found in the blood levels of vitamin D, vitamin B6, or vitamin B12 between groups. However, 50% of the hyperlipidemic patients and 54.5% of the controls exhibited vitamin D deficiency. Only the hyperlipidemic patients exhibited deficiencies of vitamins B6 and B12 in 5.4% and 3.3% of cases, respectively. In the controls, vitamin B12 level was inversely associated with total cholesterol, whereas in the hyperlipidemic patients, vitamin B6 level was inversely correlated with total cholesterol and non-HDL levels.

 The hyperlipidemic patients exhibited vitamins D, B6, and B12 deficiencies. Additionally, vitamins B6 and B12 levels were inversely correlated with total cholesterol and non-HDL levels. Our findings highlight the importance of routine evaluation of vitamin levels in patients with hyperlipidemia.

 It has been shown that hyperlipidemia occurs in 71% of patients following liver transplantation. Multiple risk factors, including obesity, diabetes mellitus, and diet, as well as the immunosuppressive medications used, influence the lipid profiles that are seen in these individuals, contributing to the multifactorial etiology of lipid problems.

 The aim of the present study is to compare the lipid profile in liver transplant recipients from living-related (LR) and deceased donors (DDs).

 This is a retrospective cross-sectional study performed at Shiraz University of Medical Science between 2005 and 2018. Patients under 18 years old who received liver transplants were included in the study and divided into 2 groups who received from LR and DDs, and lipid profiles were compared between the 2 groups.

 A total of 397 patients were included in the study; in the first group, 234 received a liver from a DD, and in the second group, 161 from an LR donor. The mean body mass index (BMI) was 17.51 ± 5.49 in the first group and 16.25 ± 3.29 in the second group. The most common underlying diseases were biliary atresia (22%) and autoimmune hepatitis (15%). The mean triglyceride (TG) and high-density lipoprotein (HDL) levels were 133 and 46 mg/dL in the first group and 118 and 54 mg/dL in the second group, while the differences were statistically significant. As age increased, there was a significant difference in the mean values of fasting blood sugar (FBS) and HDL, with FBS increasing and HDL decreasing. There was no significant difference in the use of immunosuppressant drugs between the 2 groups.

 Patients who received a liver from an LR donor have a significantly lower TG, higher HDL, and a lower cardiovascular risk.

Paraoxonase 1 (PON1) is related to high-density lipoprotein (HDL) in serum and protects against low-density lipoprotein (LDL) oxidation. This study aimed to investigate the effects of Terminalia chebula on PON1 in hyperlipidemic rats and the molecular docking effects of some compounds of this medical plant on PON1 activity.

Overall, 40 male rats (200–250 gr) were randomly divided into four groups, including the control group, the hyperlipid group, the hyperlipid group receiving 400 mg/kg of the hydroalcoholic extract of T. chebula seeds, and the hyperlipid group receiving 800 mg/kg of the hydroalcoholic extract of T. chebula seeds. The PON1 arylesterase activity in serum and the PON1 gene expression in the liver tissue underwent investigation. Then, the molecular docking effects of its compounds were studied on PON1 through in-silico studies using the AutoDock software (version 4.2.0).

T. chebula decreased (P<0.001) the serum triglycerides from 105.88±10.15 mg/dL in the hyperlipidemic group to 66.88±14.90 and 74.25±9.51 mg/dL in hyperlipidemic groups receiving 400 and 800 mg/kg of the hydroalcoholic extract of T. chebula seeds, respectively. In addition, the PON1 serum aryl esterase activity increased from 202.12±6058 in hyperlipidemic rats to 224.34±58.74 (P=0.83) and 235.80±37.05 (P=0.6) in hyperlipidemic groups receiving 400 mg/kg and 800 mg/kg of the hydroalcoholic extract of T. chebula seeds, respectively. It also demonstrated a significant effect on PON1 gene expression (P<0.001). In addition, the in-silico and docking results revealed that the main antioxidant compounds of T. chebula, such as catechin, kaempferol, and quercetin, could bind to the PON1 enzyme directly and influence the enzyme activity.

T. chebula increased PON1 activity and PON1 gene expression. However, among the plant’s compounds, catechin, kaempferol, and quercetin played the most substantial role in the PON1 activity. It seems that these compounds can be useful as co-treatments in hyperlipidemia therapies.

Liver injury and hyperlipidemia are major issues that have drawn more and more attention in recent years. The present study aimed to investigate the effects of unacylated ghrelin (UAG) on acute liver injury and hyperlipidemia in mice.

UAG was injected intraperitoneally once a day for three days. Three hours after the last administration, acute liver injury was induced by intraperitoneal injection of carbon tetrachloride (CCl4), and acute hyperlipidemia was induced by intraperitoneal injection of poloxamer 407, respectively. Twenty-four hours later, samples were collected for serum biochemistry analysis, histopathological examination, and Western blotting.

In acute liver injury mice, UAG significantly decreased liver index, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), reduced malondialdehyde (MDA) concentration and increased superoxide dismutase(SOD) in liver tissue. NF-kappa B (NF-κB) protein expression in the liver was down-regulated. In acute hyperlipidemia mice, UAG significantly decreased serum total cholesterol (TC), triglyceride (TG), ALT, and AST, as well as hepatic TG levels. Meanwhile, hepatic MDA decreased and SOD increased significantly. Moreover, UAG improved the pathological damage in the liver induced by CCl4 and poloxamer 407, respectively.

Intraperitoneal injection of UAG exhibited hepatoprotective and lipid-lowering effects on acute liver injury and hyperlipidemia, which is attributed to its anti-inflammatory and anti-oxidant activities.

 Saccharin is approximately 300 times sweeter than sucrose, and since its discovery, there has been several controversies regarding its potential toxicity as chronic saccharin consumption negatively influences biochemical parameters. Subsequently, Solanum aethiopicum is a good source of bioactive compounds that can be used to treat a variety of ailments including nervous, respiratory, visual, renal, circulatory and fertility issues. The aim of this study was to investigate the effects of ethanolic fruit extract of Solanum Aethiopicum (L.) on saccharin induced hyperlipidemia and sperm abnormalities in male Wistar rats.

 In this experimental study, 16 Wistar rats were divided into four groups (Groups 1 to 4) comprising of four Wistar Rats per group. Group 1 (control) was given distilled water and feed only, group 2 was administered saccharin (10 mg), group 3 were administered saccharin (10 mg) and 50 mg of extract, while group 4 was administered saccharin (10 mg) and 100 mg of extract. The extract was administered for 21 days, then the rats were sacrificed and blood sample was collected through cardiac puncture for Lipid profile test. Also, semen analysis was conducted to assess sperm count, motility, viability, and morphology. The results were expressed as mean ± SEM. The differences between the four groups were determined using one-way analysis of variance, and results were considered to be significant at p ≤ 0.05.

 The results showed that saccharin adversely affected lipid profile and sperm parameters in Wistar Rats. Also, ethanolic fruit extract of Solanum aethiopicum caused a significant dose-dependent increase of lipid profile and sperm parameters in Wistar Rats administered saccharin.

 Solanum aethiopicum is beneficial for treatment of sperm abnormalities and hyperlipidemia. It is recommended that the fruit be utilized as a less expensive alternative in clinical therapies for treating sperm abnormalities and hyperlipidemia.

 The aim of this study was to compare moderate- versus high-intensity statin therapy in patients with type 2 diabetes and low-density lipoprotein (LDL) cholesterol less than 130 mg/dL.

 This was a randomized, open-label, parallel design trial comprised of 79 patients randomly allocated into two groups receiving high-intensity [atorvastatin 40 mg (A40) or rosuvastatin 20 mg (R20) daily] or moderate-intensity [atorvastatin 20 mg (A20) or rosuvastatin 10 (R10) mg daily] statins for eight weeks. The variables investigated were lipid profile, high sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6).

 The percentage of decrease in LDL levels (±SD) for the high-intensity group (-35.5±25.5) was significantly greater than the moderate-intensity group (-24.6±23.5) (P=0.04). While 38.1% (n:8) of patients receiving A20 and 55% (n:11) of those being on R10 achieved the targets of≥30% reduction in the LDL level, these figures were 63.2% (n=12) and 73.8% (n=14) for A40 and R20 subgroups, respectively. Subsequently, the likelihood of achieving LDL reduction≥30%, was significantly greater with high-intensity statin therapy (OR: 3.1, 95% CI: 1.09, 8.90, P=0.03). Logistic regression analysis also showed that for every 1 mg/dL increase in the baseline LDL level, the odds of achieving the LDL reduction≥30% increased by 1.04 times [95% CI: (1.01, 1.07), P=0.003].

 Despite the general conception, moderate-intensity statins are not adequate for the majority of patients with T2DM and mild hyperlipidemia and greater numbers of patients could reach the LDL cholesterol target with high-intensity statin therapy.

The present study aimed to investigate the hypolipidemic and lipoprotein protective effects of a phenolic extract from sweet basil.

The antihyperlipidemic activity was evaluated using Triton WR-1339 and a highfat diet (HFD) induced hyperlipidemic mouse models. In the Triton model, plasma lipids were measured after 24h of treatment, whereas in the HFD model, body weight, food intake, plasma and fecal lipids were determined biweekly. After 45 days of treatment, the livers and abdominal adipose tissues were weighed and lipid measurements for each group were performed.

In both models, the phenolic extract at 100 and 200mg/kg significantly reduced plasma total cholesterol (TC), LDL-cholesterol (LDL-C), triglycerides, atherogenic index and LDL-C/HDL-C ratio and increased HDL-C. Besides, the phenolic extract significantly repressed the gain in body, liver and adipose tissue weights while the food intake was not significantly hindered. Moreover, phenolic extract decreases TC and triglycerides in the liver and adipose tissue and increases their fecal excretion. The phenolic extract exhibited a protective effect against plasma lipoprotein oxidation (IC50=4.64±0.42 µg/ml) and neutralized DPPH free radical (IC50=2.83±0.05 µg/ml) in a manner relatively similar to that exerted by butylated hydroxyanisole (synthetic antioxidant). Total phenolics in the extract represent 234.45±0.84 mg/g and HPLC analysis reveals that the extract includes four main phenolics, with caftaric acid being particularly abundant.

This data suggests that sweet basil is an interesting plant food rich in phenolic compounds that might significantly reduce hyperlipidemia and prevent atherosclerosis and related cardiovascular complications.

Staying adjacent to steel plants may raise the chance of cardiovascular disease (CVD) risk factors for their inhabitants. The present study aimed to compare some CVD risk factors in the residents of a city adjacent to the steel plant as the exposed city in comparison with the residents of a control city in the Isfahan province.

In a cross-sectional study in 2021, the data related to the prevalence rate of hypertension (HTN), diabetes mellitus (DM), Hyperlipidemia, overweight, and obesity were collected in the over 30 years old inhabitants who were living in Chamgordan as the exposed city and Ferydounshahr as the control city and underwent cardiovascular risk assessment. The data were gathered from the Iranian electronic health file system by the census sampling method.

Among the more than 30 years old population who stayed in the exposed and the control cities, the prevalence rates of CVD risk factors were as HTN (20.53% and 16.54%), DM (10.32% and 7.13%), and overweight and obesity (32.55% and 27.07%), respectively. There were no significant statistical differences between the exposed and control cities regarding HTN (P=0.471), DM (P=0.447), and overweight and obesity (P=0.355). However, hyperlipidemia was significantly more prevalent in the exposed city by 11.53% in comparison with 0.45% in the control city (P=0.001).

Except for hyperlipidemia, there was no significant statistical difference in the prevalence rates of HTN, DM, overweight, and obesity between the exposed and the control cities.

Various Allium plants were found to improve blood lipid profile. The present investigation explored the anti-hyperlipidemic potential of A. affine in a rat model of hyperlipidemia induced by glucocorticoid.

Hydroalcoholic extract was prepared by maceration method and assessed for total phenolic content. Forty-eight male Wistar rats in eight groups were studied. Group I received vehicle; group II was treated only with 400 mg/kg A. affine orally; group III was subcutaneously injected with 10 mg/kg/day dexamethasone; group IV as the reference group received dexamethasone and 40 mg/kg atorvastatin orally; groups V-VIII were treated with dexamethasone and simultaneously with 50, 100, 200 or 400 mg/kg of A. affine extract orally. All treatments were done over a period of seven days. Blood levels of glucose, lipid profile, liver enzymes and malondialdehyde (MDA) were assessed in over-fasted rats. Liver tissues were weighed and evaluated for histopathological alterations.

The amount of total phenolics content of A. affine extract was 11.24 ± 1.7 mg/g as gallic acid equivalent. Administration of A. affine extract significantly lowered the blood levels of triglycerides, total cholesterol, low-density lipoprotein (LDL)-cholesterol, very low-density lipoprotein (VLDL)-cholesterol, blood sugar, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and MDA. However, there was no significant effect on high-density lipoprotein (HDL)-cholesterol level. A. affine improved hepatic steatosis resulted from dexamethasone.

These findings suggest potential of A. affine for preventing and managing hyperlipidemia. However, more trials are needed concerning its clinical efficacy and identifying its bioactive phytochemicals and mechanisms participated in the lipid-lowering action.

Metabolic syndrome is associated with the development of chronic kidney disease. Bursera simaruba “chaca” is a medicinal plant used in Mexico for hypertension and empirical therapy.  In this study, were examined the effects of ethanol extract of B. simaruba on metabolic syndrome.

For induction of metabolic syndrome, 20% fructose was used, and it was administered in the water and food to male Wistar rats for 12 weeks, after administering ethanol extract of B. simaruba intragastrically (100 and 200 mg/kg/day) for 6 weeks, blood pressure was determined. In plasma, glucose, cholesterol, triglycerides, angiotensin II, oxide nitric, and angiotensin 1-7 were quantified. In the kidney was performed histological study and the activity of anti-oxidant enzymes was quantified. 

Rats with metabolic syndrome developed obesity, arterial hypertension, dyslipidemia, and kidney damage characterized by proliferative glomerulonephritis, necrosis, and reduced activity of anti-oxidant enzymes. These alterations were significantly ameliorated by ethanol extract of B. simaruba.

The ethanolic extract of B. simaruba showed antidyslipidemic, antihypertensive, anti-oxidant, and renoprotective effects.

Abnormality in metabolism of lipids and hyperlipidemia is a risk factor for atherosclerosis which is the major cause of cardiovascular diseases (CVDs). Several herbal drugs are used for the treatment of dyslipidemia. The present study investigates the effects of hydroalcoholic extracts of Senna extract on serum lipid profile among hyperlipidemic rats.

Forty eight male Wistar rats were randomly divided into 6 groups of 8 animals, including group 1) normal pellet diet (control), group 2) high fat diet (HFD), group, 3) HFD with 100 mg/kg Senna extract treatment, group 4) HFD with 200 mg/kg Senna extract treatment, group 5) 100 mg/kg pure Senna extract, and group 6) 200 mg/kg pure Senna extract. All the dietary regimens and Senna extract treatments were continued for 30 days. At the end of the experiment, blood samples collected from heart of rats and the lipid profile levels were measured.

The results indicated that short-term treatment by hydroalcoholic of Senna extract produced a significant reduction in the level of cholesterol, triglyceride, and LDL-C (P < 0.05), as well as an increase in HDL-C. The body weight in the HFD group was significantly higher than the other groups (P < 0.05).

Prescription of hydroalcoholic extracts of Senna is effective in the treatment of hyperlipidemia, and can inhibit the weight gain induced by HFD in rats. Some of these effects could be attributed to antioxidants activities, biological and pharmaceutical properties and other protective properties of the Senna extract requiring further investigations

Hypertension, diabetes, and hyperlipidemia are common chronic diseases in South Korea, and medication is a key factor in managing these diseases and preventing disease advancement to multimorbidity. This study aimed to evaluate the effect of chronic disease on medication intake and adherence among Koreans.

This study was conducted utilizing data collected from 5,529 individuals that participated in the Korea Health Panel Survey (KHPS) in 2014-2017. The dependent variables were medication intake and adherence, and independent variables included socioeconomic status and the type of chronic disease. The differences in the medication intake and medication adherence by sociodemographic variables and the type of chronic disease were analyzed by chi-square test. The effect of hypertension, diabetes, and hyperlipidemia on medication intake and adherence was analyzed via multiple logistic regression using SAS statistical software.

The rate of medication intake and adherence were significantly different among patients with hypertension, diabetes, and hyperlipidemia, especially lower in patients with hyperlipidemia compared to those with hypertension and diabetes. In multiple logistic regression analysis, the probability of medication intake increased in female gender, older age, medical aid, medication adherence was higher in married, lower educational level and lower household income. Compared to hyperlipidemia, patients with hypertension and diabetes had more likely to take medication as prescribed.

The importance of considering the type of chronic disease in developing and implementing public health programs aiming for improved medication adherence. Targeting better medication intake and adherence for each chronic disease could be a valuable policy strategy to effectively manage chronic diseases as well as prevent their complications.

The rise in hyperlipidemia cases is still alarming, worldwide. This study determined the effect of zinc oxide nanoparticles (ZnO NPs) on hyperlipidemia in experimental rats. Rats were assigned to six equal groups of five rats. Hyperlipidemia was induced by 7 days intraperitoneal injection of Triton X-100. Group 1 (Sham) received standard diet, Group 2 (Negative control) received 100 mg/kg Triton X-100, Group 3 (Standard) received 100 mg/ kg Triton X-100 and 10 mg/kg atorvastatin, Group 4 received 100 mg/kg Triton X-100 and 100 μg/kg ZnO NPs, Group 5 received 100 mg/kg Triton X-100 and 300 μg/kg ZnO NPs and Group 6 received 100 mg/kg Triton X-100 and 500 μg/kg ZnO NPs, orally. ZnO NPs displayed a light crystalline phase with fine peaks of ZnO wurtzite structure. ZnO showed lower antioxidant activity at concentrations of 60 and 100 μg/mL. A significant decrease in serum total cholesterol (TC), triglycerides (TG), low density lipoproteins (LDL) levels and atherogenic index with a significant increase in high densitylipoproteins (HDL) level were noticed in groups received ZnO NPs in a dose dependent manner. There was a significant decrease in alanine transaminase (ALT) level, with no significant difference in aspartate transaminase (AST) and alkaline phosphatase (ALP) levels at the highest dose. There was a significant decrease in serum antioxidant enzymes and cardiovascular biomarkers. Histologically, there was a healing in cardiac tissue following administration of ZnO NPs. ZnO NPs were shown to have antihyperlipidemic and cardiovascular protective effects by regulating lipid metabolism-related biochemical parameters.

 Cardiovascular diseases are the most important causes of death worldwide. Atherosclerosis, as a common form of cardiovascular disease, tends to involve specific areas of the circulatory system. Boron has anti-inflammatory and antioxidant properties with potential beneficial effects. In this study, we investigated the effect of Boron on histopathological changes of atherosclerotic plaque and lipid profile in hyperlipidemic rabbits.

 Male rabbits in five groups of control, sham, hyperlipidemia, treatment 1 and treatment 2 were fed on high fat diet (1% cholesterol). Treatment groups received Boron, 4 mg / kg, on the first and 20th days of experiment. Animals’ weights were measured on days 1, 21 and 60. Plasma levels of Cholesterol, LDL, HDL and TG were measured by photometric method. After 60 days, Sudan IV staining method was used for macroscopic study. Hematoxylin-eosin and Masson’s trichrome staining method were performed for quantitative analysis.

 Animals in the control and sham groups showed no significant change in serum lipid profile with no atherosclerotic plaque in aortic vessels. In the hyperlipidemia group, significant alterations in lipid profile and presence of atheroma plaques were detected. In animals receiving Boron as a protective agent, atheroma plaques were significantly less (p <0.05). This was confirmed by quantitative analysis.

 Boron ameliorates the development and progression of atherosclerotic plaques. Boron can be used alone or in combination with other drugs as anti-atherosclerotic treatment.